EDWARDS LIFESCIENCES CORPORATION (EW) FY2024 YTD Q3 P&L / Income Statement

EDWARDS LIFESCIENCES CORPORATION (EW) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

4,053,700,000 US dollars

Cost of sales

825,300,000 US dollars

Gross profit

3,228,400,000 US dollars

Operating costs, including other operating expenses (calculated)

2,162,300,000 US dollars

Operating income, net

1,066,100,000 US dollars

Other income (expense), net (calculated)

91,900,000 US dollars

Income from continuing operations before provision for income taxes

1,158,000,000 US dollars

Provision for income taxes

107,000,000 US dollars

Net income

3,785,400,000 US dollars

Transcatheter Aortic Valve Replacement

3,069,800,000 US dollars

Transcatheter Mitral and Tricuspid Therapies

247,000,000 US dollars

Surgical Structural Heart

736,900,000 US dollars

Selling, general, and administrative expenses

1,297,300,000 US dollars

Research and development expenses

781,900,000 US dollars

Intellectual property agreement and certain litigation expenses (Note 3)

27,800,000 US dollars

Change in fair value of contingent consideration liabilities (Note 9)

0 US dollars

Restructuring expenses (Note 4)

32,900,000 US dollars

Other operating expenses, net

22,400,000 US dollars

Income from discontinued operations, net of tax

2,734,400,000 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
• Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $3.79 B; to noncontrolling interests: −$3.60 M.